Lupin reports 13.5% revenue rise, 66% profit jump

Lupin Limited reported consolidated revenues of INR 227,079 million, a 13.5% increase over FY24, with profit before tax rising 65.8% to INR 40,150 million. The company's EBITDA margin improved to 24.7%.

The pharmaceutical company announced a final dividend of INR 12 per equity share and secured 52 product approvals in FY25. Lupin's U.S. business contributed 36% to global revenues while India accounted for 34%, with the company ranking eighth in the Indian Pharmaceutical Market.